Although many pharmaceutical companies have successfully developed classic chemotherapeutic agents for cancer treatment, they are plagued with side effects due to the drug conjugate's toxicity. Eikonoklastes Therapeutics has developed a unique immune conjugate technology that targets tissue factors to treat solid tumors and other pathologic conditions. With it, Eikonoklastes Therapeutics expects to provide potency and selectivity with minimal side effects.
Eikonoklastes Therapeutic’s immunoconjugate technology was discovered by its scientific founder, Dr. Zhiwei Hu, who had licensed it from the Ohio State University. He had realized the ubiquitous nature of tissue factor while working at Yale many years earlier. In his research, he identified tissue factor as a common biomarker and therapeutic target on various cancer cells and various types of solid tumors.
Eikonoklastes Therapeutics : A Novel Approach to Cancer Treatment
Currently, we are focusing on the treatment of triple-negative breast cancer, ovarian cancer, and malignant melanoma, mainly because of its lowest survival rates
Currently, Eikonoklastes Therapeutics is in the preclinical stage, and they are ramping up their efforts to start a clinical trial. Meanwhile, the company verifies its compound’s efficacy on other solid tumors, including melanoma and ovarian cancer. Eikonoklastes Therapeutics is led by visionary leaders who bring a sustained record of successful drug development in multibillion-dollar pharmaceutical companies and early-stage biotech ventures. Both Dato and Harplyn gained extensive experience in drug development while working at P&G Pharmaceuticals. Moreover, Harplyn was also the former director of new drug development at P&G Pharmaceuticals. Sam Lee, the company’s chief business officer, plays a pivotal role in guiding the company steadily down the path to future growth. With their combined leadership and technological prowess, Eikonoklastes Therapeutics is well on its way to revolutionize cancer treatment.